Brain

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

Annamycin delivering better performance 7th line than would be expected even in 2nd line for monotherapy Responders (Stable Disease or...

Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors

Phase 11 First-In-Human study designed to assess safety, tolerability, right dose for Phase 2 and early signs of efficacy of...

Rose Hill Life Sciences Executes Exclusive License Agreement with Johns Hopkins University for Restoration of Motor Function Post-Neurological Injury Using Psychedelics

BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Rose Hill Life Sciences, a global leader in the research and intellectual property...

Philips launches intelligent 3D imaging in Europe to empower faster stroke care, helping physicians save time, brain, and lives

Azurion_SmartCT_Dual_viewer SmartCT-Soft-Tissue-Dual-Phase-Cerebral-Stroke Demonstrated at LINNC Paris 2025, the company’s latest release of SmartCT delivers fast, intelligent 3D imaging in the...

Matter Neuroscience announces collaboration with Stanford Medicine combining Matter protocol with real-time fMRI neurofeedback to support emotion-based interventions in depression

This collaboration sets out to explore whether using the Matter Neuroscience protocol combined with real-time neurofeedback can influence emotional brain networks...

Sony, SCREEN, and VitroVo to Start Trial Offer of MEA System Capable of Simultaneous Measuring and Recording Data from Approximately 237,000 Electrodes

Contributing to high-definition visualization of cellular activity and supporting research into neuronal and cardiac diseases and drug discovery TOKYO, June...

Sapience Therapeutics Provides Data Update from Phase 2 Trial of Lucicebtide in Patients with Glioblastoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

-Clinical benefit and favorable safety profile as monotherapy and in combination with SOC- -Biomarker data supports MOA: decreased GBM mesenchymal...

Hyperfine Announces FDA Clearance of a New Next-Generation Swoop® System Powered by Optive AI™ Software, Delivering a Transformative Leap in Image Quality

This major Swoop® system scanner redesign and Optive AI™ software elevate the AI-powered portable MRI experience for clinicians and their...

Hyperfine Announces FDA Clearance of a New Next-Generation Swoop® System Powered by Optive AI™ Software, Delivering a Transformative Leap in Image Quality

This major Swoop® system scanner redesign and Optive AI™ software elevate the AI-powered portable MRI experience for clinicians and their...

error: Content is protected !!